{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["melas syndrome", "mitochondrial disease", "oxidative stress", "ozone therapy", "safety study"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "38054163", "DateRevised": {"Year": "2023", "Month": "12", "Day": "07"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2023", "Month": "11", "Day": "04"}], "ELocationID": ["e48261", "10.7759/cureus.48261"], "Journal": {"ISSN": "2168-8184", "JournalIssue": {"Volume": "15", "Issue": "11", "PubDate": {"Year": "2023", "Month": "Nov"}}, "Title": "Cureus", "ISOAbbreviation": "Cureus"}, "ArticleTitle": "Long-Term Safety of Systemic Ozone Therapy in a Patient With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS).", "Pagination": {"StartPage": "e48261", "MedlinePgn": "e48261"}, "Abstract": {"AbstractText": ["A patient with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like\u00a0episodes (MELAS) syndrome, a rare mitochondrial disease characterized by myopathy, epilepsy, encephalopathy, acidosis, and recurrent cerebral ischemic episodes, underwent systemic hematogenous ozone therapy for 17 years.\u00a0Despite advancements in the study of mitochondrial diseases, there are currently no available treatments for MELAS. The patient in this case has received over 280 sessions of systemic hematic ozone therapy since 2003 (from the age of 10 years) till the time of publication, without reporting any adverse effects, achieving a normal level of development considering the comorbidities. Possible mechanisms of action of systemic hematogenous ozone therapy include improved efficiency of the mitochondrial oxidative chain through the induction of antioxidant enzymes (catalase, superoxide dismutases {SOD}, peroxidase). More studies are needed to evaluate the actual safety of long-term systemic hematogenous ozone therapy in patients with mitochondrial diseases."], "CopyrightInformation": "Copyright \u00a9 2023, Romanello et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Internal Medicine, Ospedale San Pietro Fatebenefratelli, Roma, ITA."}], "LastName": "Romanello", "ForeName": "Daniele", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Internal Medicine, Ospedale San Pietro Fatebenefratelli, Roma, ITA."}], "LastName": "Rotunno", "ForeName": "Sara", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biomedical Sciences, Ozone Therapy Unit, Ospedale San Pietro Fatebenefratelli, Roma, ITA."}], "LastName": "Martinelli", "ForeName": "Mauro", "Initials": "M"}], "PublicationTypeList": ["Case Reports"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Cureus", "NlmUniqueID": "101596737", "ISSNLinking": "2168-8184"}, "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "MELAS syndrome. Koga SJ, Hodges M, Markin C, Gorman P. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1303144/ West J Med. 1995;163:379\u2013381.", "ArticleIdList": ["PMC1303144", "7483605"]}, {"Citation": "When should MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) be the diagnosis? Lorenzoni PJ, Werneck LC, Kay CS, Silvado CE, Scola RH. Arq Neuropsiquiatr. 2015;73:959\u2013967.", "ArticleIdList": ["26517220"]}, {"Citation": "Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Kaufmann P, Engelstad K, Wei Y, et al. Neurology. 2011;77:1965\u20131971.", "ArticleIdList": ["PMC3235358", "22094475"]}, {"Citation": "A 3-year clinical follow-up of adult patients with 3243AG in mitochondrial DNA. Majamaa-Voltti KA, Winqvist S, Remes AM, et al. Neurology. 2006;66:1470\u20131475.", "ArticleIdList": ["16717204"]}, {"Citation": "El-Hattab AW, Almannai M, Scaglia F, et al. GeneReviews [Internet] Seattle, WA: University of Washington; 2001. MELAS."}, {"Citation": "Arginine and citrulline for the treatment of MELAS syndrome. El-Hattab AW, Almannai M, Scaglia F. J Inborn Errors Metab Screen. 2017;5", "ArticleIdList": ["PMC5519148", "28736735"]}, {"Citation": "MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. El-Hattab AW, Adesina AM, Jones J, Scaglia F. Mol Genet Metab. 2015;116:4\u201312.", "ArticleIdList": ["26095523"]}, {"Citation": "The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Di Mauro R, Cantarella G, Bernardini R, et al. Int J Mol Sci. 2019;20", "ArticleIdList": ["PMC6387239", "30717203"]}, {"Citation": "Clinical features of MELAS and its relation with A3243G gene point mutation. Zhang J, Guo J, Fang W, Jun Q, Shi K. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680494/ Int J Clin Exp Pathol. 2015;8:13411\u201313415.", "ArticleIdList": ["PMC4680494", "26722549"]}, {"Citation": "Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS) Kobayashi Y, Momoi MY, Tominaga K, et al.  https://pubmed.ncbi.nlm.nih.gov/1715668/ Am J Hum Genet. 1991;49:590\u2013599.", "ArticleIdList": ["PMC1683152", "1715668"]}, {"Citation": "The biological and molecular action of ozone and its derivatives: state-of-the-art, enhanced scenarios, and quality insights. Travagli V, Iorio EL. Int J Mol Sci. 2023;24", "ArticleIdList": ["PMC10218271", "37239818"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "11", "Day": "3"}, {"Year": "2023", "Month": "12", "Day": "6", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "6", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "12", "Day": "6", "Hour": "4", "Minute": "19"}, {"Year": "2023", "Month": "11", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["38054163", "PMC10695090", "10.7759/cureus.48261"]}}], "PubmedBookArticle": []}